NCT03605849View on ClinicalTrials.gov

A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

PHASE3CompletedINTERVENTIONAL

Enrollment

662

Participants

Timeline

Start Date

February 14, 2019

Primary Completion Date

September 7, 2021

Study Completion Date

September 7, 2021

Conditions

Attention Deficit DisorderAttention Deficit Hyperactivity Disorder

Interventions

DRUG

Centanafadine SR

200mg, BID, oral tablets

Trial Locations (1)

90230

For additional information regarding sites, contact 844-687-8522, Culver City

All Listed Sponsors

lead

Otsuka Pharmaceutical Development & Commercialization, Inc.

INDUSTRY

NCT03605849 - A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder | Biotech Hunter | Biotech Hunter